Benjamin P. Saylor

Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.

Regarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.

The investigators reported that “the risk of recurrence was significantly lower following BLC (HR=0.67, 95% CI: 0.51-0.89) than WLC.”

The investigators reported that pCR was significantly higher in the neoadjuvant chemotherapy + RNU group vs RNU alone, with an OR of 2.49 (95% CI: 1.75 – 3.54, P < .001).

At baseline, 16 patients had an IIEF-EF score of 11-21. These patients reported significant improvement in IIEF-EF score at Times 2 and 4, according to the authors.

"An educated patient is one that's always going to want to be more involved in trying to make themselves better; they're going to be an empowered patient,” says Thomas J. Mueller, MD.

“No doubt about it, this is unequivocally a positive trial by the rPFS criteria. Quite positive,” says A. Oliver Sartor, MD.

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.

The FDA's decision was based on results from the OASIS trial, in which the Revi tibial neurostimulator device demonstrated significant efficacy for treating urge urinary incontinence in women.

"The addition of an immune checkpoint inhibitor after tri- or tetra-modality therapy might improve long-term outcomes for patients with bladder cancer,” said Maria De Santis, MD.

"In EV-103 dose escalation/cohort A, the safety profile of the combination was manageable, with no new safety concerns observed at nearly 4 years of follow-up," said Shilpa Gupta, MD.

The proportion of patients who discontinued initial ARI treatment was 30.4% for darolutamide compared with 40.8% for enzalutamide and 46.0% for apalutamide.

"PRP does not seem to be effective in treating men with erectile dysfunction, at least as a monotherapy,” said Ranjith Ramasamy, MD.

“We looked at safety issues within 12 months after the implantation, and they were minor—some pain problems, some wound-healing problems, but no serious adverse events,” said John Heesakkers, MD, PhD.

“What we found is that hypertension is an independent risk factor for worsened survival outcomes and mortality outcomes across the board on multivariable and Kaplan Meier analysis,” said Sohail Dhanji, MD.

Investigators retrospectively studied patients with Peyronie disease and diabetes mellitus between 2007 and 2022.

"Patients with a prior BPH procedure were on average older than our HoLEP controls; however, there were no other differences in preoperative patient characteristics or postoperative functional outcomes," said Nicholas S. Dean, MD.

Clinical progression-free survival following the first cycle of radioligand therapy was 6.3 months, and overall survival following the first cycle was 21.4 months.

In cohort B of the phase 2 Keynote-057 trial, pembrolizumab led to antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer.

By the data cut-off date of January 31, 2023, investigators reported that 30% of patients with nonmetastatic castration-resistant prostate cancer had received darolutamide for at least 4 years, and 24% of were still receiving the agent.

The FDA will be evaluating findings from cohorts A and K from the phase 1b/2 EV-103 trial.

The regimen consists of an alpha prostate-specific membrane antigen-targeted radionuclide therapy (225Ac-J591), an androgen receptor signaling inhibitor, and pembrolizumab.

"We want to make sure that independent urology continues to thrive by recruiting new people to independent urology. That's what we're going to try and do," said Evan R. Goldfischer, MD.

"Specifically for our transgender and gender-diverse patients, there are still insurance issues and access issues in general," said Diana K. Bowen, MD.

In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.

In an interview during the 2022 LUGPA Annual Meeting, Ashley Ross, MD, PhD, discussed angoing advances and unmet needs in prostate cancer.

The findings are from the EV-103 trial and were presented at the 2022 ESMO Congress by lead investigator Jonathan E. Rosenberg, MD.

“Further analysis of patient subsets with this unique trial should help inform future research,” said lead investigator Mohamad Allaf, MD.

"Our goal is to understand the lived experiences of people on gender-affirming hormonal therapy, as it relates to their urinary and sexual health,” said first author Paige De Rosa, MD, urology resident at the University of Iowa, Iowa City.